




211

CLAIMS

1. A compound of Formula (I):



wherein Q is:

**(IIa)****(IIb)**

or

R₁ is selected from the group consisting of:

- (i) C₁₋₁₆ alkyl, and
 C₁₋₁₆ alkyl substituted by substituent(s) independently selected
 from the group consisting of:
- halogen,
 - hydroxy,
 - oxo,
 - C₁₋₅ alkoxy,
 - C₁₋₅ alkoxy substituted by substituent(s) independently selected
 from the group consisting of:
 - carbocyclic aryl,
 - heterocyclyl, and
 - heterocyclyl substituted by C₁₋₅ alkyl,
 - C₁₋₅ alkylcarbonyloxy,
 - carbocyclyloxy,
 - carbocyclic aryloxy,

•carbocyclic aryloxy substituted by substituent(s) independently selected from the group consisting of:

- halogen,
- hydroxy,
- carboxy,
- carbamoyl,
- nitro,
- cyano,
- amino,
- carbocyclic aryl,
- carbocyclic aryl substituted by C₁₋₅ alkoxy,
- C₁₋₅ alkoxy,
- C₁₋₅ alkoxy substituted by halogen,
- C₁₋₅ alkyl, and
- C₁₋₅ alkyl substituted by substituent(s) independently selected from the group consisting of:

- halogen,
- hydroxy,
- carboxy,
- oxo,
- mono-C₁₋₅ alkylamino,
- di-C₁₋₅ alkylamino,
- mono-C₁₋₅ alkylamino substituted by carbocyclic aryl,
- di-C₁₋₅ alkylamino substituted by carbocyclic aryl,
- mono-C₁₋₅ alkylamino substituted by halogenated carbocyclic aryl,

213

- di-C₁₋₅ alkylamino substituted by halogenated carbocyclic aryl,
- carbocyclic aryl carbonylamino, and
- carbocyclic aryl carbonylamino substituted by halogen,
- heterocycloxy,
- heterocycloxy substituted by substituent(s) independently selected from the group consisting of:

- halogen,
- hydroxy,
- carboxy,
- carbamoyl,
- nitro,
- cyano,
- amino,
- carbocyclic aryl,
- carbocyclic aryl substituted by C₁₋₅ alkoxy,
- C₁₋₅ alkoxy,
- C₁₋₅ alkoxy substituted by substituent(s) independently selected from the group consisting of:

- halogen,
- hydroxy, and
- carboxy,
- C₁₋₅ alkyl, and
- C₁₋₅ alkyl substituted by substituent(s) independently selected from the group consisting of:

- halogen,
- hydroxy, and

214

- carboxy,
- substituted heterocyclyl-ethylideneaminoxy,
- C₁₋₅ alkoxy carbonyl,
- C₁₋₅ alkoxy carbonyl substituted by carbocyclic aryl,
- mono-C₁₋₅ alkylaminocarbonyl,
- di-C₁₋₅ alkylaminocarbonyl,
- mono-C₁₋₅ alkylamino,
- mono-C₁₋₅ alkylamino substituted by substituent(s) independently selected from the group consisting of:

- cyano,
- carbocyclic aryl, and
- heterocyclyl,
- di-C₁₋₅ alkylamino,
- di-C₁₋₅ alkylamino substituted by substituent(s) independently selected from the group consisting of:

- cyano,
- carbocyclic aryl, and
- heterocyclyl,
- mono-carbocyclic arylamino,
- mono-carbocyclic arylamino substituted by substituent(s) independently selected from the group consisting of:

- halogen,
- hydroxy,
- carboxy,
- carbamoyl,
- nitro,
- cyano,
- amino,

215

- carbocyclic aryl,
- carbocyclic aryl substituted by C₁₋₅ alkoxy,
- C₁₋₅ alkoxy,
- C₁₋₅ alkoxy substituted by substituent(s) independently selected from the group consisting of:
 - halogen,
 - hydroxy, and
 - carboxy,
- C₁₋₅ alkyl, and
- C₁₋₅ alkyl substituted by substituent(s) independently selected from the group consisting of:
 - halogen,
 - hydroxy, and
 - carboxy,
- di-carbocyclic arylamino,
- di-carbocyclic arylamino substituted by substituent(s) independently selected from the group consisting of:
 - halogen,
 - hydroxy,
 - carboxy,
 - carbamoyl,
 - nitro,
 - cyano,
 - amino,
 - carbocyclic aryl,
 - carbocyclic aryl substituted by C₁₋₅ alkoxy,
 - C₁₋₅ alkoxy,
 - C₁₋₅ alkoxy substituted by substituent(s) independently

216

selected from the group consisting of:

•••halogen,

•••hydroxy, and

•••carboxy,

••C₁₋₅ alkyl, and

••C₁₋₅ alkyl substituted by substituent(s) independently

selected from the group consisting of:

•••halogen,

•••hydroxy, and

•••carboxy,

•mono-heterocyclamino,

•mono-heterocyclamino substituted by substituent(s)

independently selected from the group consisting of:

••halogen,

••hydroxy,

••carboxy,

••carbamoyl,

••nitro,

••cyano,

••amino,

••carbocyclic aryl,

••carbocyclic aryl substituted by C₁₋₅ alkoxy,

••C₁₋₅ alkoxy,

••C₁₋₅ alkoxy substituted by substituent(s) independently

selected from the group consisting of:

•••halogen,

•••hydroxy, and

•••carboxy,

217

- C₁₋₅ alkyl, and

- C₁₋₅ alkyl substituted by substituent(s) independently

selected from the group consisting of:

- halogen,

- hydroxy, and

- carboxy,

- di-heterocyclylamino,

- di-heterocyclylamino substituted by substituent(s) independently

selected from the group consisting of:

- halogen,

- hydroxy,

- carboxy,

- carbamoyl,

- nitro,

- cyano,

- amino,

- carbocyclic aryl,

- carbocyclic aryl substituted by C₁₋₅ alkoxy,

- C₁₋₅ alkoxy,

- C₁₋₅ alkoxy substituted by substituent(s) independently

selected from the group consisting of:

- halogen,

- hydroxy, and

- carboxy,

- C₁₋₅ alkyl, and

- C₁₋₅ alkyl substituted by substituent(s) independently

selected from the group consisting of:

- halogen,

218

••hydroxy, and

••carboxy,

•C₁₋₅ alkylcarbonylamino,•C₁₋₅ alkylcarbonylamino substituted by substituent(s)

independently selected from the group consisting of:

••C₁₋₅ alkylcarbonylamino,

••carbocyclic arylcarbonylamino, and

••heterocyclyl,

•C₁₋₅ alkoxy carbonylamino,

•carbocyclic arylcarbonylamino,

•heterocyclyl carbonylamino,

•carbocyclic arylsulfonylamino,

•carbocyclic arylsulfonylamino substituted by substituent(s)

independently selected from the group consisting of:

••nitro,

••C₁₋₅ alkyl,••mono-C₁₋₅ alkylamino, and••di-C₁₋₅ alkylamino,•C₁₋₅ alkylthio,•C₁₋₅ alkylthio substituted by substituent(s) independently selected

from the group consisting of:

••mono-carbocyclic arylaminocarbonyl,

••mono-carbocyclic arylaminocarbonyl substituted by
halogen,

••di-carbocyclic arylaminocarbonyl,

••di-carbocyclic arylaminocarbonyl substituted by halogen,

••mono-carbocyclic arylamino,

••mono-carbocyclic arylamino substituted by halogen,

219

- di-carbocyclic arylamino,
 - di-carbocyclic arylamino substituted by halogen,
 - carbocyclic aryl, and
 - carbocyclic aryl substituted by substituent(s)
- independently selected from the group consisting of:
- halogen, and
 - C₁₋₅ alkoxy,
- carbocyclic arylthio,
- carbocyclic arylthio substituted by substituent(s) independently selected from the group consisting of:
- halogen,
 - C₁₋₅ alkyl, and
 - C₁₋₅ alkyl substituted by halogen,
- carbocyclic arylsulfinyl,
- carbocyclic arylsulfinyl substituted by substituent(s)
- independently selected from the group consisting of:
- halogen,
 - C₁₋₅ alkyl, and
 - C₁₋₅ alkyl substituted by halogen,
- carbocyclic arylsulfonyl,
- carbocyclic arylsulfonyl substituted by substituent(s)
- independently selected from the group consisting of:
- halogen,
 - C₁₋₅ alkyl, and
 - C₁₋₅ alkyl substituted by halogen,
- heterocyclylthio,
- heterocyclylthio substituted by substituent(s) independently selected from the group consisting of:

220

- nitro, and
- C₁₋₅ alkyl,
- C₃₋₆ cycloalkyl,
- C₃₋₆ cycloalkyl substituted by C₁₋₅ alkyl,
- C₃₋₆ cycloalkyl substituted by carbocyclic aryl,
- C₃₋₆ cycloalkenyl,
- carbocyclyl,
- carbocyclyl substituted by substituent(s) independently selected from the group consisting of:
 - halogen,
 - C₁₋₅ alkyl,
 - C₁₋₅ alkoxy,
 - C₂₋₅ alkenyl, and
 - C₂₋₅ alkenyl substituted by substituent(s) independently selected from the group consisting of:
 - carbocyclic aryl, and
 - carbocyclic aryl substituted by C₁₋₅ alkylsulfinyl,
- carbocyclic aryl,
- carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
 - halogen,
 - hydroxy,
 - carboxy,
 - carbamoyl,
 - cyano,
 - nitro,
 - amino,

221

- C₁₋₅ alkylcarbonylamino,
- C₃₋₆ cycloalkylcarbonylamino,
- C₁₋₅ alkyl,
- C₁₋₅ alkyl substituted by substituent(s) independently selected from the group consisting of:

- halogen,
- hydroxy,
- carboxy,
- carbamoyl,
- oxo,
- carbocyclic aryl,
- heterocyclyl,
- mono-carbocyclic arylamino,
- di-carbocyclic arylamino,
- mono-carbocyclic arylamino substituted by substituent(s) independently selected from the group consisting of:

- halogen,
- nitro,
- C₁₋₅ alkyl,
- C₁₋₅ alkoxy, and
- C₁₋₅ alkoxy substituted by halogen,

- di-carbocyclic arylamino substituted by substituent(s) independently selected from the group consisting of:

- halogen,
- nitro,
- C₁₋₅ alkyl,

222

••••C₁₋₅ alkoxy, and••••C₁₋₅ alkoxy substituted by halogen,••C₂₋₅ alkenyl,••C₁₋₅ alkoxy,••C₁₋₅ alkoxy substituted by substituent(s) independently

selected from the group consisting of:

•••halogen, and

•••carbocyclic aryl,

••carbocyclic aryloxy,

••C₁₋₅ alkoxy carbonyl,••C₁₋₅ alkyl carbonyloxy,••mono-C₁₋₅ alkylamino,••di-C₁₋₅ alkylamino,

••mono-carbocyclic arylamino,

••mono-carbocyclic arylamino substituted by halogen,

••di-carbocyclic arylamino,

••di-carbocyclic arylamino substituted by halogen,

••mono-carbocyclic arylaminocarbonyl,

••mono-carbocyclic arylaminocarbonyl substituted by

substituent(s) selected from the group consisting of:

•••halogen,

•••nitro,

•••C₁₋₅ alkyl,•••C₁₋₅ alkoxy, and•••C₁₋₅ alkoxy substituted by halogen,

••di-carbocyclic arylaminocarbonyl,

••di-carbocyclic arylaminocarbonyl substituted by

substituent(s) selected from the group consisting of:

223

- halogen,
- nitro,
- C₁₋₅ alkyl,
- C₁₋₅ alkoxy, and
- C₁₋₅ alkoxy substituted by halogen,
- mercapto,
- C₁₋₅ alkylthio,
- C₁₋₅ alkylthio substituted by halogen,
- C₁₋₅ alkylsulfonyl,
- C₃₋₆ cycloalkyl,
- carbocyclic aryl, and
- heterocyclyl,
- heterocyclyl, and
- heterocyclyl substituted by substituent(s) independently selected from the group consisting of:
 - halogen,
 - hydroxy,
 - carboxy,
 - carbamoyl,
 - cyano,
 - nitro,
 - amino,
 - C₁₋₅ alkyl,
 - C₁₋₅ alkyl substituted by substituent(s) independently selected from the group consisting of:
 - halogen,
 - hydroxy,
 - carboxy, and

224

••carbamoyl,

••C₁₋₅ alkyl substituted by carbocyclic aryl,••C₁₋₅ alkoxy,••C₁₋₅ alkoxy substituted by halogen,••C₁₋₅ alkoxy substituted by carbocyclic aryl,

••carbocyclic aryl, and

••carbocyclic aryl substituted by halogen,

(ii) C₂₋₈ alkenyl, and

C₂₋₈ alkenyl substituted by substituent(s) independently selected from the group consisting of:

•halogen,

•oxo,

•C₁₋₅ alkoxy,•C₁₋₅ alkoxy substituted by carbocyclic aryl,

•carbocyclic aryl,

•carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

••halogen,

••hydroxy,

••nitro,

••C₁₋₅ alkyl,••C₁₋₅ alkyl substituted by halogen,••C₁₋₅ alkoxy, and••C₁₋₅ alkoxy substituted by halogen,

•heterocyclyl, and

•heterocyclyl substituted by substituent(s) independently selected from the group consisting of:

••hydroxy,

225

- nitro,
 - C₁₋₅ alkyl, and
 - C₁₋₅ alkoxy,
- (iii) C₂₋₅ alkynyl, and
C₂₋₅ alkynyl substituted by carbocyclic aryl,
- (iv) C₃₋₁₂ cycloalkyl, and
C₃₋₁₂ cycloalkyl substituted by substituent(s) independently
selected from the group consisting of:
- C₁₋₅ alkyl,
 - C₁₋₅ alkyl substituted by substituent(s) independently selected
from the group consisting of:
 - hydroxy,
 - oxo, and
 - carbocyclic aryl,
 - mono-C₁₋₅ alkylamino,
 - mono-C₁₋₅ alkylamino substituted by carbocyclic aryl,
 - di-C₁₋₅ alkylamino,
 - di-C₁₋₅ alkylamino substituted by carbocyclic aryl,
 - carbocyclic arylcarbonylamino,
 - carbocyclic aryl, and
 - carbocyclic aryl substituted by halogen,
- (v) C₃₋₆ cycloalkenyl, and
C₃₋₆ cycloalkenyl substituted by C₁₋₅ alkyl,
- (vi) carbocyclyl, and
carbocyclyl substituted by substituent(s) independently selected
from the group consisting of:
- hydroxy, and
 - nitro,

- (vii) carbocyclic aryl, and
carbocyclic aryl substituted by substituent(s) independently
selected from the group consisting of:
- halogen,
 - hydroxy,
 - cyano,
 - nitro,
 - C₁₋₁₀ alkyl,
 - C₁₋₁₀ alkyl substituted by substituent(s) independently selected
from the group consisting of:
 - halogen,
 - hydroxy,
 - carboxy,
 - carbamoyl,
 - oxo,
 - C₁₋₅ alkoxy,
 - carbocyclic aryloxy,
 - mono-C₁₋₅ alkylamino-N-oxy,
 - di-C₁₋₅ alkylamino-N-oxy,
 - mono-C₁₋₅ alkylamino,
 - di-C₁₋₅ alkylamino,
 - mono-C₁₋₅ alkylamino substituted by carbocyclic aryl,
 - di-C₁₋₅ alkylamino substituted by carbocyclic aryl,
 - mono-carbocyclic arylamino,
 - di-carbocyclic arylamino,
 - carbocyclylimino,
 - carbocyclylimino substituted by carbocyclic aryl,
 - mono-carbocyclic arylamino,

- di-carbocyclic arylamino,
 - mono-carbocyclic arylamino substituted by C₁₋₅ alkoxy,
 - di-carbocyclic arylamino substituted by C₁₋₅ alkoxy,
 - mono-carbocyclic arylaminocarbonyl,
 - di-carbocyclic arylaminocarbonyl,
 - mono-carbocyclic arylaminocarbonyl substituted by C₁₋₅ alkoxy,
 - di-carbocyclic arylaminocarbonyl substituted by C₁₋₅ alkoxy,
 - carbocyclic aryl,
 - carbocyclic aryl substituted by substituent(s)
- independently selected from the group consisting of:

- halogen,
 - C₁₋₅ alkyl, and
 - C₁₋₅ alkyl substituted by halogen,
 - heterocyclyl, and
 - heterocyclyl substituted by C₁₋₅ alkyl,
- C₂₋₅ alkenyl,
 - C₂₋₅ alkenyl substituted by carbocyclic aryl,
 - C₁₋₉ alkoxy,
 - C₁₋₉ alkoxy substituted by substituent(s) independently selected from the group consisting of:
- hydroxy,
 - halogen,
 - carboxy,
 - mono-C₁₋₅ alkylamino,
 - di-C₁₋₅ alkylamino,
 - carbocyclic aryl,

228

••halogenated carbocyclic aryl,
••heterocyclyl,
••heterocyclyl substituted by substituent(s) independently
selected from the group consisting of:

•••halogen,
•••heterocyclyl, and
•••heterocyclyl substituted by substituent(s)
independently selected from the group consisting
of:

••••halogen,
••••C₁₋₅ alkyl, and
••••C₁₋₅ alkyl substituted by halogen,

•C₂₋₅ alkenyloxy,
•C₃₋₆ cycloalkoxy,
•C₁₋₅ alkylcarbonyloxy,
•carbocyclic aryloxy,
•carbocyclic aryloxy substituted by substituent(s) independently
selected from the group consisting of:

••halogen,
••hydroxy,
••carboxy,
••carbamoyl,
••cyano,
••nitro,
••amino,
••C₁₋₅ alkyl,
••C₁₋₅ alkyl substituted by substituent(s) independently
selected from the group consisting of:

229

- halogen,
- hydroxy,
- carboxy, and
- carbamoyl,
- C₁₋₅ alkoxy, and
- C₁₋₅ alkoxy substituted by halogen,
- heterocyclyloxy,
- heterocyclyloxy substituted by substituent(s) independently selected from the group consisting of:
 - halogen,
 - hydroxy,
 - carboxy,
 - carbamoyl,
 - cyano,
 - nitro,
 - amino,
 - C₁₋₅ alkyl,
 - C₁₋₅ alkyl substituted by substituent(s) independently selected from the group consisting of:
 - halogen,
 - hydroxy,
 - carboxy, and
 - carbamoyl,
 - C₁₋₅ alkoxy, and
 - C₁₋₅ alkoxy substituted by halogen,
- (carbocyclic aryl)S(O)₂O,
- carboxy,
- carbamoyl,

- C₁₋₅ alkoxycarbonyl,
- mono-C₁₋₅ alkylaminocarbonyl,
- di-C₁₋₅ alkylaminocarbonyl,
- mono-C₁₋₅ alkylaminocarbonyl substituted by carbocyclic aryl,
- di-C₁₋₅ alkylaminocarbonyl substituted by carbocyclic aryl,
- mono-carbocyclic arylaminocarbonyl,
- di-carbocyclic arylaminocarbonyl,
- mono-carbocyclic arylaminocarbonyl substituted by C₁₋₅ alkyl,
- di-carbocyclic arylaminocarbonyl substituted by C₁₋₅ alkyl,
- amino,
- mono-C₁₋₅ alkylamino,
- di-C₁₋₅ alkylamino,
- mono-C₁₋₅ alkylamino substituted by cyano,
- di-C₁₋₅ alkylamino substituted by cyano,
- mono-carbocyclic arylamino,
- di-carbocyclic arylamino,
- C₁₋₅ alkylcarbonylamino,
- C₃₋₆ cycloalkylcarbonylamino,
- C₂₋₅ alkynylcarbonylamino,
- C₂₋₅ alkynylcarbonylamino substituted by carbocyclic aryl,
- C₁₋₅ alkoxycarbonylamino,
- carbocyclic arylsulfonylamino,
- carbocyclic arylsulfonylamino substituted by C₁₋₅ alkyl,
- (carbocyclic aryl)NHC(O)NH,
- (carbocyclic aryl)NHC(O)NH substituted by C₁₋₅ alkoxy,
- (carbocyclic aryl)NHC(O)NH substituted by halogenated C₁₋₅ alkoxy,
- carbocyclic aryl azo,

- carbocyclic aryl azo substituted by mono-C₁₋₅ alkylamino,
- carbocyclic aryl azo substituted by di-C₁₋₅ alkylamino,
- C₁₋₅ alkylthio,
- C₁₋₅ alkylthio substituted by halogen,
- carbocyclic arylthio,
- carbocyclic arylthio substituted by substituent(s) independently selected from the group consisting of:

- halogen,
- nitro,
- cyano, and
- C₁₋₅ alkyl,

- aminosulfonyl,
- heterocyclylthio,
- C₁₋₅ alkylsulfonyl,
- mono-C₁₋₅ alkylaminosulfonyl,
- di-C₁₋₅ alkylaminosulfonyl,
- heterocyclylsulfonyl,
- C₃₋₆ cycloalkyl,
- C₃₋₆ cycloalkyl substituted by C₁₋₅ alkyl,
- carbocyclic aryl,
- carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

- C₁₋₇ alkyl, and
- C₁₋₇ alkyl substituted by halogen,

- heterocyclyl, and
- heterocyclyl substituted by substituent(s) independently selected from the group consisting of:

- C₁₋₅ alkyl,

232

••carbocyclic aryl, and

••halogenated carbocyclic aryl,

•C₁₋₅ alkoxy carbonyl substituted by carbocyclic aryl, and(viii) heterocycl~~y~~**1**, andheterocycl~~y~~**1** substituted by substituent(s) independently selected from the group consisting of:

•halogen,

•hydroxy,

•carboxy,

•carbamoyl,

•cyano,

•nitro,

•amino,

•C₁₋₅ alkyl,•C₁₋₅ alkyl substituted by substituent(s) independently selected

from the group consisting of:

••halogen,

••hydroxy,

••carboxy,

••carbamoyl,

••oxo,

••C₁₋₅ alkylcarbonyloxy,

••carbocyclic arylcarbonylamino,

••carbocyclic arylcarbonylamino substituted by halogen,

••C₁₋₅ alkoxycarbonyl,••C₁₋₅ alkylthio,••C₁₋₅ alkylthio substituted by carbocyclic aryl,••C₁₋₅ alkylthio substituted by halogenated carbocyclic

233

aryl,

••carbocyclic aryl,

••carbocyclic aryl substituted by substituent(s)

independently selected from the group consisting of:

•••halogen, and

•••nitro,

••heterocyclyl, and

••heterocyclyl substituted by substituent(s) independently
selected from the group consisting of:

•••halogen,

•••C₁₋₅ alkyl, and

•••C₁₋₅ alkyl substituted by halogen,

•C₁₋₅ alkoxy,

•C₁₋₅ alkoxy substituted by halogen,

•C₁₋₅ alkoxy substituted by carbocyclic aryl,

•carbocyclic aryloxy,

•carbocyclic aryloxy substituted by substituent(s) independently
selected from the group consisting of:

••halogen,

••nitro,

••cyano,

••hydroxy,

••carboxy,

••carbamoyl,

••amino,

••C₁₋₅ alkyl,

••C₁₋₅ alkyl substituted by substituent(s) independently

selected from the group consisting of:

234

- halogen,
- hydroxy,
- carboxy, and
- carbamoyl,
- mono-C₁₋₅ alkylamino,
- di-C₁₋₅ alkylamino,
- C₁₋₅ alkylcarbonylamino,
- C₃₋₆ cycloalkylcarbonylamino,
- C₁₋₅ alkoxy,
- C₁₋₅ alkoxy substituted by halogen,
- C₃₋₆ cycloalkyl,
- C₂₋₅ alkenyl,
- C₂₋₅ alkynyl,
- carboxy,
- C₁₋₅ alkoxycarbonyl,
- mono-C₁₋₅ alkylaminocarbonyl,
- di-C₁₋₅ alkylaminocarbonyl,
- mono-C₃₋₆ cycloalkylaminocarbonyl,
- di-C₃₋₆ cycloalkylaminocarbonyl,
- mono-C₁₋₅ alkylaminocarbonylamino,
- di-C₁₋₅ alkylaminocarbonylamino,
- mono-C₃₋₆ cycloalkylaminocarbonylamino,
- di-C₃₋₆ cycloalkylaminocarbonylamino,
- C₁₋₅ alkylthio,
- C₁₋₅ alkylthio substituted by halogen,
- C₁₋₅ alkylsulfinyl,
- C₁₋₅ alkylsulfinyl substituted by halogen,
- C₁₋₅ alkylsulfonyl, and

235

- C₁₋₅ alkylsulfonyl substituted by halogen,
- heterocycloxy,
- heterocycloxy substituted by substituent(s) independently selected from the group consisting of:
 - halogen,
 - nitro,
 - hydroxy,
 - carboxy,
 - carbamoyl,
 - cyano,
 - amino,
 - C₁₋₅ alkyl,
 - C₁₋₅ alkyl substituted by substituent(s) independently selected from the group consisting of:
 - halogen,
 - hydroxy,
 - carboxy, and
 - carbamoyl,
 - C₁₋₅ alkoxy, and
 - C₁₋₅ alkoxy substituted by halogen,
- mono-C₁₋₅ alkylamino,
- di-C₁₋₅ alkylamino,
- C₁₋₅ alkylcarbonylamino,
- C₁₋₅ alkylthio,
- C₂₋₅ alkenylthio,
- carbocyclic arylthio,
- carbocyclic arylthio substituted by halogen,
- carbocyclic arylthio substituted by C₁₋₅ alkoxy carbonyl,

- heterocyclylthio,
- heterocyclylthio substituted by C₁₋₅ alkyl,
- C₁₋₅ alkylsulfinyl,
- C₁₋₅ alkylsulfonyl,
- carbocyclic arylsulfinyl,
- carbocyclic arylsulfinyl substituted by halogen,
- carbocyclic arylsulfonyl,
- carbocyclic arylsulfonyl substituted by halogen,
- carbocyclic arylsulfonyl substituted by C₁₋₅ alkyl,
- C₁₋₅ alkoxy carbonyl,
- C₁₋₅ alkoxy carbonyl substituted by carbocyclic aryl,
- carbocyclic aryl,
- carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
 - halogen,
 - nitro,
 - C₁₋₅ alkyl,
 - C₁₋₅ alkyl substituted by halogen,
 - C₁₋₅ alkoxy, and
 - C₁₋₅ alkoxy substituted by halogen,
- heterocyclyl, and
- heterocyclyl substituted by substituent(s) independently selected from the group consisting of:
 - halogen,
 - C₁₋₅ alkyl,
 - C₁₋₅ alkyl substituted by halogen,
 - C₁₋₅ alkoxy, and
 - C₁₋₅ alkoxy carbonyl;

R₂ is halogen, C₁₋₅ alkyl, C₁₋₅ alkyl substituted by halogen, C₁₋₅ alkyl substituted by hydroxy, C₁₋₅ alkyl substituted by carbocyclic aryl, C₁₋₅ alkyl substituted by halogenated carbocyclic aryl, C₁₋₅ alkyl substituted by heterocyclyl, C₁₋₅ alkyl substituted by halogenated heterocyclyl, C₂₋₅ alkenyl, C₂₋₅ alkynyl, C₁₋₅ alkoxy, C₁₋₅ alkoxy substituted by halogen, C₁₋₅ alkylthio, -N(R_{2a})(R_{2b}); wherein R_{2a} and R_{2b} are each independently hydrogen, C₁₋₅ alkyl, or C₁₋₅ alkyl substituted by substituent(s) independently selected from the group consisting of:

- halogen,
- hydroxy,
- carboxy,
- carbamoyl,
- C₁₋₅ alkoxy,
- amino,
- C₃₋₆ cycloalkyl,
- carbocyclic aryl,
- carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

- halogen,
- C₁₋₅ alkyl,
- C₁₋₅ alkoxy,
- C₁₋₅ alkyl substituted by halogen,
- C₁₋₅ alkoxy substituted by halogen, and
- SO₂NH₂,

- heterocyclyl, and
- heterocyclyl substituted by substituent(s) independently selected from the group consisting of:

238

- halogen,
- C₁₋₅ alkyl,
- C₁₋₅ alkoxy,
- C₁₋₅ alkyl substituted by halogen, and
- C₁₋₅ alkoxy substituted by halogen,


C₃₋₆ cycloalkyl, carbocyclic aryl, carbocyclic aryl substituted by
substituent(s) independently selected from the group consisting of:

- halogen,
- C₁₋₅ alkyl,
- C₁₋₅ alkoxy,
- C₁₋₅ alkyl substituted by halogen, and
- C₁₋₅ alkoxy substituted by halogen,

heterocyclyl, or heterocyclyl substituted by substituent(s) independently
selected from the group consisting of:

- halogen,
- C₁₋₅ alkyl,
- C₁₋₅ alkoxy,
- C₁₋₅ alkyl substituted by halogen, and
- C₁₋₅ alkoxy substituted by halogen;

L is selected from the group consisting of Formulae (III), (IIIa), (IIIb),
(IV), (IVa), and (IVb);



wherein R_3 and R_4 are each independently hydrogen or C_{1-5} alkyl; and A and B are each independently a single bond, $-CH_2-$, or $-(CH_2)_2-$; Z_1 , Z_2 , Z_3 , and Z_4 are each independently hydrogen, halogen, C_{1-5} alkyl, C_{1-5} alkyl substituted by halogen, C_{1-5} alkyl substituted by hydroxy, C_{1-5} alkyl substituted by carbocyclic aryl, C_{1-5} alkyl substituted by halogenated carbocyclic aryl, C_{1-5} alkyl substituted by heterocyclyl, C_{1-5} alkyl substituted by halogenated heterocyclyl, C_{2-5} alkenyl, C_{2-5} alkynyl, C_{3-6} cycloalkyl, C_{1-5} alkoxy, C_{1-5} alkoxy substituted by halogen, mono- C_{1-5} alkyl amino, di- C_{1-5} alkyl amino, C_{1-5} alkylthio, carbocyclic aryl, substituted carbocyclic aryl, heterocyclyl, or substituted heterocyclyl; or R_2 and Z_2 are bonded to each other to form a ring and $-R_2-Z_2-$ is $-(CH_2)_n-$ or $-(CH_2)_o-CH=CH-(CH_2)_p-$; wherein one $-CH_2-$ group of $-R_2-Z_2-$ can optionally be replaced by $C(O)$, NR_6 , O , S , $S(O)$, or $S(O)_2$; wherein n is 2, 3, 4, 5, or 6; o and p are each independently 0, 1, 2, 3, or 4 provided that $o+p = 0, 1, 2, 3, \text{ or } 4$; and R_6 is hydrogen, C_{1-5} alkyl, or substituted C_{1-5} alkyl;

and

Y represents:

- (i) $-C(O)NR_5-$, $-C(S)NR_5-$, $-C(O)O-$, $-S(O)_2-$, $-C(O)-$, $-C(S)-$, or $-(CH_2)_m-$ when L is selected from the group consisting of Formulae (III), (IIIa), and (IIIb); or
- (ii) $-C(O)NR_5-$, $-C(S)NR_5-$, $-C(O)O-$, or $-OC(O)-$ when L is selected from the group consisting of Formulae (IV), (IVa), and (IVb);

wherein R_5 is hydrogen or C_{1-5} alkyl; and m is 0, 1, 2, 3, 4, or 5;

wherein carbocyclic aryl is phenyl, naphthyl, anthranyl, phenanthryl, or biphenyl;

carbocyclyl is 10,11-dihydro-5-oxo-dibenzo[a,d]cycloheptyl, 1-

oxo-indanyl, 7,7-dimethyl-2-oxo-bicyclo[2.2.1]heptyl, 9*H*-fluorenyl, 9-oxo-fluorenyl, acenaphthyl, anthraquinonyl, *C*-fluoren-9-ylidene, indanyl, indenyl, menthyl, 1,2,3,4-tetrahydro-naphthyl, or bicyclo[2.2.1]heptenyl;

heterocyclyl is 1,2,3,4-tetrahydro-isoquinolyl, 1,2,3-thiadiazolyl, 1,2,3-triazolyl, 1,2-dihydro-3-oxo-pyrazolyl, 1,3,4-thiadiazolyl, 1,3-dioxo-isoindolyl, 1,3-dioxolanyl, 1*H*-indolyl, 1*H*-pyrrolo[2,3-*c*]pyridyl, 1*H*-pyrrolyl, 1-oxo-3*H*-isobenzofuranyl, 2,2',5',2''-terthiophenyl, 2,2'-bithiophenyl, 2,3-dihydro-1-oxo-isoindolyl, 2,3-dihydro-benzo[1,4]dioxinyl, 2,3-dihydro-benzofuryl, 2,4-dihydro-3-oxo-pyrazolyl, 2*H*-benzopyranyl, 2-oxo-benzopyranyl, 2-oxo-pyrrolidinyl, 3,4-dihydro-2*H*-benzo[1,4]oxazinyl, 3,4-dihydro-2*H*-benzo[*b*][1,4]dioxepinyl, 4*H*-benzo[1,3]dioxinyl, 4*H*-benzopyranyl, 4-oxo-1,5,6,7-tetrahydro-indolyl, 4-oxo-3,4-dihydro-phthalazinyl, 4-oxo-benzopyranyl, 9,10,10-trioxo-thioxanthenyl, 9*H*-carbazolyl, 9*H*-xanthenyl, azetidiny, benzimidazolyl, benzo[1,3]dioxolyl, benzo[2,1,3]oxadiazolyl, benzo[1,2,5]oxadiazolyl, benzo[*b*]thienyl, benzofuryl, benzothiazolyl, cinnolyl, furyl, imidazo[2,1-*b*]thiazolyl, imidazolyl, isoxazolyl, morpholino, morpholinyl, oxazolyl, oxolanyl, piperazyl, piperidyl, piridyl, pyrazolo[5,1-*b*]thiazolyl, pyrazolyl, pyrazinyl, pyridyl, pyrimidyl, pyrrolidyl, quinolyl, quinoxalyl, thiazolidyl, thiazolyl, thienyl, thiolanyl, 2,3-dihydro-benzofuryl, tetrahydro-thienyl, or benzofuranyl;

halogen is fluoro, chloro, bromo, or iodo;

or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

2. The compound according to claim 1 wherein Q is Formula (IIa);
Z₁ is hydrogen, halogen, C₁₋₅ alkyl, C₁₋₅ alkyl substituted by halogen, C₃₋₆ cycloalkyl, C₁₋₅ alkoxy, C₁₋₅ alkoxy substituted by halogen, or C₁₋₅ alkylthio; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
3. The compound according to claim 2 wherein R₁ is selected from the group

consisting of:

- (i) C₁₋₁₀ alkyl, and
C₁₋₁₀ alkyl substituted by substituent(s) independently selected
from the group consisting of:
- halogen,
 - oxo,
 - C₁₋₅ alkoxy,
 - C₁₋₅ alkoxy substituted by carbocyclic aryl,
 - C₁₋₅ alkylcarbonyloxy,
 - C₁₋₅ alkoxy carbonyl,
 - C₁₋₅ alkoxy carbonyl substituted by carbocyclic aryl,
 - carbocyclic aryloxy, and
 - carbocyclic aryloxy substituted by substituent(s) independently
selected from the group consisting of:
 - halogen,
 - nitro,
 - C₁₋₅ alkyl, and
 - C₁₋₅ alkyl substituted by oxo,
 - heterocyclyloxy,
 - heterocyclyloxy substituted by C₁₋₅ alkyl,
 - mono-carbocyclic arylamino,
 - di-carbocyclic arylamino,
 - carbocyclic arylsulfonylamino,
 - carbocyclic arylsulfonylamino substituted by C₁₋₅ alkyl,
 - C₁₋₅ alkylthio,
 - C₁₋₅ alkylthio substituted by carbocyclic aryl,
 - carbocyclic arylthio,
 - carbocyclic arylthio substituted by halogen,

- carbocyclic arylthio substituted by C₁₋₅ alkyl,
- carbocyclic arylsulfonyl,
- carbocyclic arylsulfonyl substituted by halogen,
- heterocyclylthio,
- heterocyclylthio substituted by C₁₋₅ alkyl,
- C₃₋₆ cycloalkyl,
- C₃₋₆ cycloalkenyl,
- carbocyclyl,
- carbocyclyl substituted by C₁₋₅ alkoxy,
- carbocyclic aryl, and
- carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

- halogen,
- nitro,
- C₁₋₅ alkyl, and
- C₁₋₅ alkyl substituted by substituent(s) independently selected from the group consisting of:

- halogen,
- carbocyclic aryl, and
- heterocyclyl,

- C₁₋₅ alkoxy,
- C₁₋₅ alkoxy substituted by halogen,
- C₁₋₅ alkoxy substituted by carbocyclic aryl,
- carbocyclic aryloxy,
- mono-carbocyclic arylaminocarbonyl, and
- mono-carbocyclic arylaminocarbonyl substituted by substituent(s) selected from the group consisting of:

- halogen,

243

- C₁₋₅ alkyl,
 - C₁₋₅ alkoxy, and
 - C₁₋₅ alkoxy substituted by halogen,
 - di-carbocyclic arylaminocarbonyl, and
 - di-carbocyclic arylaminocarbonyl substituted by
- substituent(s) selected from the group consisting of:
- halogen,
 - C₁₋₅ alkyl,
 - C₁₋₅ alkoxy, and
 - C₁₋₅ alkoxy substituted by halogen,
 - C₁₋₅ alkylthio,
 - C₁₋₅ alkylthio substituted by halogen,
 - C₁₋₅ alkylsulfonyl,
 - carbocyclic aryl, and
 - heterocyclyl,
 - heterocyclyl, and
 - heterocyclyl substituted by substituent(s) independently selected
- from the group consisting of:
- C₁₋₅ alkyl,
 - C₁₋₅ alkoxy,
 - C₁₋₅ alkoxy substituted by carbocyclic aryl,
 - carbocyclic aryl, and
 - carbocyclic aryl substituted by halogen,
- (ii) C₂₋₅ alkenyl, and
- C₂₋₅ alkenyl substituted by substituent(s) independently selected
- from the group consisting of:
- carbocyclic aryl, and
 - carbocyclic aryl substituted by substituent(s) independently

selected from the group consisting of:

- nitro,
- halogen,
- C₁₋₅ alkyl,
- C₁₋₅ alkyl substituted by halogen,
- C₁₋₅ alkoxy, and
- C₁₋₅ alkoxy substituted by halogen,

(iii) C₃₋₆ cycloalkyl, and

C₃₋₆ cycloalkyl substituted by substituent(s) independently
selected from the group consisting of:

- C₁₋₅ alkyl,
- C₁₋₅ alkyl substituted by carbocyclic aryl,
- carbocyclic arylcarbonylamino, and
- carbocyclic aryl,

(iv) carbocyclyl, and

carbocyclyl substituted by nitro,

(v) carbocyclic aryl, and

carbocyclic aryl substituted by substituent(s) independently
selected from the group consisting of:

- halogen,
- cyano,
- nitro,
- C₁₋₉ alkyl, and
- C₁₋₉ alkyl substituted by substituent(s) independently selected

from the group consisting of:

- halogen,
- oxo,
- mono-carbocyclic arylaminocarbonyl,

245

- di-carbocyclic arylaminocarbonyl,
- mono-carbocyclic arylaminocarbonyl substituted by C₁₋₅ alkoxy,
- di-carbocyclic arylaminocarbonyl substituted by C₁₋₅ alkoxy,
- carbocyclic aryloxy,
- carbocyclic aryl, and
- carbocyclic aryl substituted by substituent(s)
independently selected from the group consisting of:
 - halogen,
 - C₁₋₅ alkyl, and
 - C₁₋₅ alkyl substituted by halogen,
- heterocyclyl, and
- heterocyclyl substituted by C₁₋₅ alkyl,
- C₂₋₅ alkenyl,
- C₁₋₇ alkoxy,
- C₁₋₇ alkoxy substituted by halogen,
- C₁₋₇ alkoxy substituted by carbocyclic aryl,
- C₃₋₆ cycloalkoxy,
- carbocyclic aryloxy, and
- carbocyclic aryloxy substituted by substituent(s) independently
selected from the group consisting of:
 - halogen,
 - nitro, and
 - C₁₋₅ alkoxy
- heterocyclyloxy, and
- heterocyclyloxy substituted by substituent(s) independently
selected from the group consisting of:

246

- halogen,
- C₁₋₅ alkyl, and
- C₁₋₅ alkyl substituted by halogen,
- C₁₋₅ alkoxy carbonyl,
- mono-C₁₋₅ alkylaminocarbonyl,
- di-C₁₋₅ alkylaminocarbonyl,
- mono-C₁₋₅ alkylaminocarbonyl substituted by carbocyclic aryl,
- di-C₁₋₅ alkylaminocarbonyl substituted by carbocyclic aryl,
- mono-carbocyclic arylaminocarbonyl,
- di-carbocyclic arylaminocarbonyl,
- mono-carbocyclic arylaminocarbonyl substituted by C₁₋₅ alkyl,
- di-carbocyclic arylaminocarbonyl substituted by C₁₋₅ alkyl,
- mono-C₁₋₅ alkylamino,
- di-C₁₋₅ alkylamino,
- C₁₋₅ alkylthio,
- C₁₋₅ alkylthio substituted by halogen,
- C₁₋₅ alkylsulfonyl,
- carbocyclic aryl, and
- carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

- C₁₋₇ alkyl, and
- C₁₋₇ alkyl substituted by halogen,

- (vi) heterocyclyl, and
 heterocyclyl substituted by substituent(s) independently selected from the group consisting of:

- halogen,
- C₁₋₅ alkyl, and
- C₁₋₅ alkyl substituted by substituent(s) independently selected

247

from the group consisting of:

- halogen,
- oxo,
- carbocyclic aryl,
- carbocyclic aryl substituted by halogen,
- heterocyclyl, and
- heterocyclyl substituted by substituent(s) independently

selected from the group consisting of:

- halogen,
- C₁₋₅ alkyl, and
- C₁₋₅ alkyl substituted by halogen,

- C₁₋₅ alkoxy,
 - C₁₋₅ alkylthio,
 - carbocyclic arylthio,
 - C₁₋₅ alkylsulfonyl,
 - carbocyclic arylsulfonyl,
 - carbocyclic arylsulfonyl substituted by halogen,
 - carbocyclic arylsulfonyl substituted by C₁₋₅ alkyl,
 - C₁₋₅ alkoxycarbonyl,
 - carbocyclic aryl, and
 - carbocyclic aryl substituted by substituent(s) independently
- selected from the group consisting of:

- halogen,
- nitro, and
- C₁₋₅ alkyl,

- heterocyclyl, and
 - heterocyclyl substituted by substituent(s) independently selected
- from the group consisting of:

248

- halogen,
- C₁₋₅ alkyl, and
- C₁₋₅ alkyl substituted by halogen;

wherein carbocyclic aryl is phenyl, naphthyl, or anthranyl;

carbocyclyl is 1-oxo-indanyl, 9*H*-fluorenyl, 9-oxo-fluorenyl, anthraquinonyl, *C*-fluoren-9-ylidene, indanyl, or menthyl;

heterocyclyl is 1,2,3,4-tetrahydro-isoquinolyl, 1,2,3-thiadiazolyl, 1,2,3-triazolyl, 1,3-dioxo-isoindolyl, 1*H*-indolyl, 1*H*-pyrrolyl, 2,3-dihydro-1-oxo-isoindolyl, 2,3-dihydro-benzo[1,4]dioxinyl, 2*H*-benzopyranyl, 2-oxo-benzopyranyl, 2-oxo-pyrrolidinyl, 4-oxo-benzopyranyl, 9*H*-xanthenyl, benzo[1,3]dioxolyl, benzo[2,1,3]oxadiazolyl, benzo[1,2,5]oxadiazolyl, benzo[*b*]thienyl, furyl, isoxazolyl, morpholinyl, oxazolyl, pyrazolyl, pyridyl, pyrimidyl, pyrrolidyl, quinolyl, quinoxalyl, thiazolyl, thienyl, imidazolyl, or piperazyl;

halogen is fluoro, chloro, bromo, or iodo;

or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

4. The compound according to claim 3 wherein:

R₂ is halogen, C₁₋₅ alkyl, C₁₋₅ alkoxy, -N(R_{2a})(R_{2b}), or heterocyclyl; wherein R_{2a} and R_{2b} are each independently hydrogen, C₁₋₅ alkyl, C₁₋₅ alkyl substituted by hydroxy, C₁₋₅ alkyl substituted by carbocyclic aryl, C₁₋₅ alkyl substituted by heterocyclyl, C₃₋₆ cycloalkyl, or carbocyclic aryl;

L is selected from the group consisting of Formulae (IIIa) and (IVa);

wherein R₃ and R₄ are each independently hydrogen or C₁₋₅ alkyl; and A and B are each independently a single bond, -CH₂-, or -(CH₂)₂-;

Z₁ is hydrogen, halogen, C₁₋₅ alkyl, C₁₋₅ alkyl substituted by halogen, C₁₋₅

alkoxy, or C₁₋₅ alkylthio; Z₂ is hydrogen, halogen, or C₁₋₅ alkyl; or
 R₂ and Z₂ are bonded to each other to form a ring and -R₂-Z₂- is -NR₆-
 CH=CH-; wherein R₆ is hydrogen or C₁₋₅ alkyl; and

Y represents:

- (i) -C(O)NR₅-, -C(S)NR₅-, -C(O)O-, -S(O)₂-, -C(O)-, or -(CH₂)_m-
 when L is selected from the group consisting of Formula (IIIa); or
 - (ii) -C(O)NR₅- or -C(O)O- when L is selected from the group
 consisting of Formula (IVa);
- wherein R₅ is hydrogen or C₁₋₅ alkyl; and m is 0, 1, or 2;

or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

5. The compound according to claim 4 wherein R₁ is selected from the group consisting of:

- (i) C₁₋₅ alkyl substituted by substituent(s) independently selected from the group consisting of:
 - hydroxy,
 - carbocyclic aryl,
 - carbocyclic aryl substituted by halogen, and
 - C₁₋₅ alkylthio,
- (ii) C₃₋₆ cycloalkyl, and
- (iii) carbocyclic aryl, and
 carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
 - halogen,
 - nitro,
 - cyano,
 - C₁₋₅ alkyl,
 - C₁₋₅ alkyl substituted by halogen,

250

- C₁₋₅ alkoxy,
 - C₁₋₅ alkoxy substituted by halogen,
 - C₁₋₅ alkoxy substituted by carbocyclic aryl,
 - carbocyclic aryloxy, and
 - carbocyclic aryloxy substituted by C₁₋₅ alkoxy,
- (iv) heterocyclyl, and
- heterocyclyl substituted by substituent(s) independently selected from the group consisting of:
- halogen,
 - C₁₋₅ alkyl,
 - carbocyclic aryl, and
 - carbocyclic aryl substituted by halogen;

R₂ is -N(R_{2a})(R_{2b}) or heterocyclyl; wherein R_{2a} and R_{2b} are each independently hydrogen or C₁₋₅ alkyl;

Z₁ is hydrogen, C₁₋₅ alkyl, or C₁₋₅ alkylthio; Z₂ is hydrogen or C₁₋₅ alkyl; or

R₂ and Z₂ are bonded to each other to form a ring and -R₂-Z₂- is -NR₆-CH=CH-; wherein R₆ is hydrogen or C₁₋₅ alkyl;

L is Formula (IIIa) or (IVa), wherein R₃ and R₄ are hydrogen, A is a single bond and B is a single bond or -CH₂-;

and

Y represents:

- (i) -C(O)NH-, -C(S)NH-, -C(O)-, or -CH₂- when L is selected from the group consisting of Formula (IIIa); or
- (ii) -C(O)NH- when L is selected from the group consisting of Formula (IVa);

wherein carbocyclic aryl is phenyl or naphthyl;

251

heterocyclyl is furyl, 1*H*-indolyl, morpholinyl, oxazolyl, piperidyl, pyridyl, pyrrolidyl, or 9*H*-xanthenyl;

halogen is fluoro, chloro, or bromo;

or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

6. The compound according to claim 5 wherein R₁ is selected from the group consisting of:

- (i) carbocyclic aryl, and
carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
 - halogen,
 - C₁₋₅ alkyl,
 - C₁₋₅ alkyl substituted by halogen,
 - C₁₋₅ alkoxy, and
 - C₁₋₅ alkoxy substituted by halogen,
 - (ii) heterocyclyl, and
heterocyclyl substituted by halogen;
- and

Z₁ is hydrogen, C₁₋₅ alkyl, or C₁₋₅ alkylthio; Z₂ is hydrogen or C₁₋₅ alkyl;

wherein carbocyclic aryl is phenyl;

heterocyclyl is furyl, pyridyl, or pyrrolidyl;

halogen is fluoro, chloro, or bromo;

or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

7. The compound according to claim 1 selected from the group consisting of:

N-(*cis*-4-{[6-(*dimethylamino*)pyrimidin-4-yl]amino}cyclohexyl)-3,4-difluorobenzamide;

N-(*cis*-4-{[6-(*dimethylamino*)-2-methylpyrimidin-4-yl]amino}cyclohexyl)-4-fluorobenzamide;

4-chloro-*N*-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)-3-fluorobenzamide;

N-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)-3,5-difluorobenzamide;

3-chloro-*N*-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)-4-(trifluoromethoxy)benzamide;

3-chloro-4-fluoro-*N*-(*cis*-4-{[2-methyl-6-(methylamino)pyrimidin-4-yl]amino}cyclohexyl)benzamide;

N-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)-3-fluorobenzamide;

4-chloro-*N*-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)benzamide;

N-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)-3-fluoro-5-(trifluoromethyl)benzamide;

N-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)-3,5-bis(trifluoromethyl)benzamide;

3-chloro-4-fluoro-*N*-(*cis*-4-[(2-methyl-6-piperidin-1-yl)pyrimidin-4-yl]amino)cyclohexyl}benzamide;

3-chloro-4-fluoro-*N*-(*cis*-4-[(2-methyl-6-morpholin-4-yl)pyrimidin-4-yl]amino)cyclohexyl}benzamide;

3-chloro-4-fluoro-*N*-(*cis*-4-[(7-methyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl]amino)cyclohexyl}benzamide;

3,4,5-trifluoro-*N*-(*cis*-4-[(7-methyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl]amino)cyclohexyl}benzamide;

3,4,5-trifluoro-*N*-(*cis*-4-{[2-methyl-6-(methylamino)pyrimidin-4-yl]amino}cyclohexyl)benzamide;

cis-*N*-(3,4-difluorophenyl)-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexanecarboxamide;

1-(4-chlorophenyl)-*N*-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)cyclopentanecarboxamide;

3-(2-chloro-6-fluorophenyl)-*N*-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)-5-methylisoxazole-4-carboxamide;

N-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)-2-(4-methoxyphenoxy)-5-nitrobenzamide;

N-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)-5-iodo-2-furamide;

N-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)-2-(ethylthio)-2,2-diphenylacetamide;

N-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)-9*H*-xanthene-9-carboxamide;

N-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)-*N'*-[1-(1-naphthyl)ethyl]urea;

N-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)-*N'*-(3,4,5-trimethoxyphenyl)urea;

N-(5-chloro-2,4-dimethoxyphenyl)-*N'*-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)urea;

N-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)-*N'*-(2,4,6-tribromophenyl)urea;

N-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)-*N'*-mesitylthiourea;

N-(2,6-diethylphenyl)-*N'*-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)thiourea;

N-(2,4-dichloro-6-methylphenyl)-*N'*-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)thiourea;

N-(5-chloro-2,4-dimethoxyphenyl)-*N'*-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)thiourea;

N-[4-bromo-2-(trifluoromethyl)phenyl]-*N'*-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)thiourea;

N-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)-3-nitrobenzamide;

N-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexyl]-3,4-diethoxy-benzamide;

N-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexyl]-3-ethoxy-benzamide;

N-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexyl]-3,5-diethoxy-benzamide;

N-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexyl]-3-isopropoxy-benzamide;

3-bromo-*N*-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexyl]-4-fluoro-benzamide;

4-difluoromethoxy-*N*-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexyl]-benzamide;

4-chloro-*N*-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexyl]-3-methyl-benzamide;

3-difluoromethoxy-*N*-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexyl]-benzamide;

3-chloro-*N*-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexyl]-4-methyl-benzamide;

4-bromo-*N*-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexyl]-benzamide;

N-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexyl]-3,5-dimethoxy-benzamide;

4-cyano-*N*-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexyl]-benzamide;

N-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexyl]-4-methoxy-benzamide;

3-cyano-*N*-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexyl]-benzamide;

N-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexyl]-3-methoxy-benzamide;

N-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexyl]-4-fluoro-3-methyl-benzamide;

4-bromo-*N*-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexyl]-3-methyl-benzamide;

N-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexyl]-3-fluoro-4-methyl-benzamide;

N-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexyl]-3-ethyl-benzamide;

3-bromo-*N*-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexyl]-benzamide;

N-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexyl]-3-fluoro-4-trifluoromethyl-benzamide;

N-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexyl]-4-trifluoromethoxy-benzamide;

N-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexyl]-4-methyl-benzamide;

N-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexyl]-3-methyl-benzamide;

N-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexyl]-4-trifluoromethyl-benzamide;

2,2-difluoro-benzo[1,3]dioxole-5-carboxylic acid[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexyl]-amide;

N-{*cis*-4-[(1*H*-indol-2-ylmethyl)-amino]-cyclohexyl}-2,*N,N'*-trimethyl-pyrimidine-4,6-diamine;

2,*N,N'*-trimethyl-*N'*-[*cis*-4-(3-trifluoromethoxy-benzylamino)-cyclohexyl]-pyrimidine-4,6-diamine;

N-[*cis*-4-(3,4-difluoro-benzylamino)-cyclohexyl]-2,*N,N'*-trimethyl-pyrimidine-4,6-diamine;

1-(3,4-dimethoxy-phenyl)-3-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexyl]-urea;

1-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexyl]-3-(2-ethoxy-phenyl)-urea;

1-(4-benzyloxy-phenyl)-3-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexyl]-urea;

3,5-dibromo-*N*-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexyl]-benzamide;

3-bromo-4-chloro-*N*-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexyl]-benzamide;

4-chloro-*N*-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexyl]-3-trifluoromethyl-benzamide;

2-(3,5-bis-trifluoromethyl-phenyl)-*N*-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexyl]-2-hydroxy-acetamide;

N-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexylmethyl]-3-fluoro-4-trifluoromethyl-benzamide;

N-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexylmethyl]-3-trifluoromethoxy-benzamide;

N-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexylmethyl]-3-methoxy-benzamide;

4-chloro-*N*-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexylmethyl]-benzamide;

N-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexylmethyl]-3-trifluoromethyl-benzamide;

N-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexylmethyl]-4-trifluoromethyl-benzamide;

N-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexylmethyl]-3-methyl-benzamide;

N-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexylmethyl]-3,5-difluoro-benzamide;

N-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexylmethyl]-3-ethyl-benzamide;

2,2-difluoro-benzo[1,3]dioxole-5-carboxylic acid [*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexylmethyl]-amide;

N-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexylmethyl]-3-fluoro-4-methyl-benzamide;

N-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexylmethyl]-4-fluoro-benzamide;

3,4-dichloro-*N*-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexylmethyl]-benzamide;

4-bromo-*N*-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexylmethyl]-benzamide;

N-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexylmethyl]-3,4-difluoro-benzamide;

3,5-dichloro-*N*-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexylmethyl]-benzamide;

3-chloro-*N*-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexylmethyl]-4-fluoro-benzamide;

N-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexylmethyl]-4-fluoro-3-methyl-benzamide; and

3-chloro-*N*-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexylmethyl]-benzamide;

or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

8. The compound according to claim 1 selected from the group consisting of:

N-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)-3,4-difluorobenzamide;

N-(*cis*-4-{[6-(dimethylamino)-2-ethylpyrimidin-4-yl]amino}cyclohexyl)-3,4-difluorobenzamide;

3-chloro-*N*-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)-4-fluorobenzamide;

3,4-dichloro-*N*-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)benzamide;

3-chloro-*N*-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)-5-fluorobenzamide;

N-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)-3,4,5-trifluorobenzamide;

5-bromo-*N*-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)nicotinamide;

N-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)-4-fluoro-3-(trifluoromethyl)benzamide;

N-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)-3-(trifluoromethyl)benzamide;

N-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)-3-(trifluoromethoxy)benzamide;

3,5-dichloro-*N*-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)benzamide;

3-chloro-*N*-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)benzamide;

3-chloro-4-fluoro-*N*-{*cis*-4-[(2-methyl-6-pyrrolidin-1-yl)pyrimidin-4-yl]amino}cyclohexyl}benzamide;

N-(*cis*-4-{[6-(dimethylamino)-2-ethylpyrimidin-4-yl]amino}cyclohexyl)-3,4,5-trifluorobenzamide;

cis-*N*-(3-chloro-4-fluorophenyl)-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexanecarboxamide;

N-(*cis*-4-{[2-benzyl-6-(dimethylamino)pyrimidin-4-yl]amino}cyclohexyl)-3-chloro-4-fluorobenzamide;

cis-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}-*N*-(3,4,5-trifluorophenyl)cyclohexanecarboxamide;

N-(4-bromo-2,6-dimethylphenyl)-*N'*-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)urea;

N-(4-bromo-2,6-dimethylphenyl)-*N'*-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)thiourea;

N-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)-*N'*-(3,4,5-trimethoxyphenyl)thiourea;

N-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)-*N'*-(2,4,6-tribromophenyl)thiourea;

5-bromo-furan-2-carboxylic acid [*cis*-4-(6-dimethylamino-2-methylpyrimidin-4-ylamino)-cyclohexyl]-amide;

N-[*cis*-4-(3,5-dimethoxy-benzylamino)-cyclohexyl]-2,*N'*,*N'*-trimethylpyrimidine-4,6-diamine;

N-[*cis*-4-(3-bromo-benzylamino)-cyclohexyl]-2,*N'*,*N'*-trimethylpyrimidine-4,6-diamine;

1-[*cis*-4-(6-dimethylamino-2-methylpyrimidin-4-ylamino)-cyclohexyl]-3-(3-methoxyphenyl)-urea;

1-(3,5-difluorophenyl)-3-[*cis*-4-(6-dimethylamino-2-methylpyrimidin-4-ylamino)-cyclohexyl]-urea;

N-[*cis*-4-(6-dimethylamino-2-methylsulfanyl-pyrimidin-4-ylamino)-cyclohexyl]-3,4-difluoro-benzamide;

N-[*cis*-4-(6-dimethylamino-5-methyl-pyrimidin-4-ylamino)-cyclohexyl]-3,4-difluoro-benzamide;

N-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexylmethyl]-3,5-bis-trifluoromethyl-benzamide; and

N-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexylmethyl]-4-trifluoromethoxy-benzamide;

or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

9. The compound according to claim 2 wherein:

R_1 represents:

- (i) hydrogen, $-\text{CO}_2^t\text{Bu}$, or $-\text{CO}_2\text{Bn}$ (Bn is a benzyl group) when L is selected from the group consisting of Formulae (III), (IIIa), and (IIIb); or
- (ii) hydrogen, C_{1-5} alkyl, substituted C_{1-5} alkyl, Bn, or substituted Bn when L is selected from the group consisting of Formulae (IV), (IVa), and (IVb);

wherein R_3 and R_4 are each independently hydrogen or C_{1-5} alkyl; and A and B are each independently a single bond, $-\text{CH}_2-$, or $-(\text{CH}_2)_2-$;

R_2 is halogen, C_{1-5} alkyl, C_{1-5} alkoxy, $-\text{N}(\text{R}_{2a})(\text{R}_{2b})$, or heterocyclyl;

wherein R_{2a} and R_{2b} are each independently hydrogen, C_{1-5} alkyl, C_{1-5} alkyl substituted by hydroxy, C_{1-5} alkyl substituted by carbocyclic aryl, C_{1-5} alkyl substituted by heterocyclyl, C_{3-6} cycloalkyl, or carbocyclic aryl;

Z_1 is hydrogen, halogen, C_{1-5} alkyl, C_{1-5} alkyl substituted by halogen, C_{1-5} alkoxy, or C_{1-5} alkylthio; Z_2 is hydrogen, halogen, or C_{1-5} alkyl; or

R_2 and Z_2 are bonded to each other to form a ring and $-\text{R}_2-\text{Z}_2-$ is $-\text{NR}_6-\text{CH}=\text{CH}-$; wherein R_6 is hydrogen or C_{1-5} alkyl;

and

261

Y represents:

- (i) a single bond when L is selected from the group consisting of Formulae (III), (IIIa), and (IIIb); or
- (ii) -C(O)O- when L is selected from the group consisting of Formulae (IV), (IVa), and (IVb);

or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

10. The compound according to claim 9 wherein:

R₁ represents:

- (i) hydrogen, -CO₂Bu, or -CO₂Bn (Bn is a benzyl group) when L is selected from the group consisting of Formula (IIIa); or
- (ii) hydrogen, C₁₋₅ alkyl, substituted C₁₋₅ alkyl, Bn, or substituted Bn when L is selected from the group consisting of Formula (IVa);

wherein R₃ and R₄ are each hydrogen; and A and B are each independently a single bond or -CH₂-;

R₂ is -N(R_{2a})(R_{2b}) or heterocyclyl; wherein R_{2a} and R_{2b} are each independently hydrogen or C₁₋₅ alkyl;

Z₁ is hydrogen, C₁₋₅ alkyl, or C₁₋₅ alkylthio; Z₂ is hydrogen or C₁₋₅ alkyl; or

R₂ and Z₂ are bonded to each other to form a ring and -R₂-Z₂- is -NR₆-CH=CH-; wherein R₆ is hydrogen or C₁₋₅ alkyl;

and

Y represents:

- (i) a single bond when L is selected from the group consisting of Formula (IIIa); or
- (ii) -C(O)O- when L is selected from the group consisting of Formula (IVa);

heterocyclyl is furyl, 1*H*-indolyl, morpholinyl, oxazolyl, piperidyl, pyridyl, pyrrolidyl, or 9*H*-xanthenyl;

or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

11. The compound according to claim 1 wherein Q is Formula (IIb);

R₂ is C₁₋₅ alkyl substituted by hydroxy, C₁₋₅ alkyl substituted by carbocyclic aryl, C₁₋₅ alkyl substituted by halogenated carbocyclic aryl, C₁₋₅ alkyl substituted by heterocyclyl, C₁₋₅ alkyl substituted by halogenated heterocyclyl, C₂₋₅ alkenyl, C₂₋₅ alkynyl, or -N(R_{2a})(R_{2b}); wherein R_{2a} and R_{2b} are each independently hydrogen, C₁₋₅ alkyl, or C₁₋₅ alkyl substituted by substituent(s) independently selected from the group consisting of:

- halogen,
- hydroxy,
- carboxy,
- carbamoyl,
- C₁₋₅ alkoxy,
- amino,
- C₃₋₆ cycloalkyl,
- carbocyclic aryl,
- carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

- halogen,
- C₁₋₅ alkyl,
- C₁₋₅ alkoxy,
- C₁₋₅ alkyl substituted by halogen,
- C₁₋₅ alkoxy substituted by halogen, and
- SO₂NH₂,

- heterocyclyl, and
- heterocyclyl substituted by substituent(s) independently selected from the group consisting of:

263

- halogen,
- C₁₋₅ alkyl,
- C₁₋₅ alkoxy,
- C₁₋₅ alkyl substituted by halogen, and
- C₁₋₅ alkoxy substituted by halogen,

carbocyclic aryl, carbocyclic aryl substituted by substituent(s)

independently selected from the group consisting of:

- halogen,
- C₁₋₅ alkyl,
- C₁₋₅ alkoxy,
- C₁₋₅ alkyl substituted by halogen, and
- C₁₋₅ alkoxy substituted by halogen,

heterocyclyl, or heterocyclyl substituted by substituent(s) independently

selected from the group consisting of:

- halogen,
- C₁₋₅ alkyl,
- C₁₋₅ alkoxy,
- C₁₋₅ alkyl substituted by halogen, and
- C₁₋₅ alkoxy substituted by halogen;

or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

12. The compound according to claim 11 wherein R₁ is selected from the group consisting of:

- (i) C₁₋₁₀ alkyl, and
- C₁₋₁₀ alkyl substituted by substituent(s) independently selected from the group consisting of:
- halogen,
 - hydroxy,
 - oxo,

- C₁₋₅ alkoxy,
- C₁₋₅ alkoxy substituted by carbocyclic aryl,
- C₁₋₅ alkylcarbonyloxy,
- C₁₋₅ alkoxy carbonyl,
- C₁₋₅ alkoxy carbonyl substituted by carbocyclic aryl,
- carbocyclic aryloxy, and
- carbocyclic aryloxy substituted by substituent(s) independently selected from the group consisting of:

- halogen,
 - nitro,
 - C₁₋₅ alkyl, and
 - C₁₋₅ alkyl substituted by oxo,
- heterocyclyloxy,
- heterocyclyloxy substituted by C₁₋₅ alkyl,
- mono-carbocyclic arylamino,
- di-carbocyclic arylamino,
- carbocyclic arylsulfonylamino,
- carbocyclic arylsulfonylamino substituted by C₁₋₅ alkyl,
- C₁₋₅ alkylthio,
- C₁₋₅ alkylthio substituted by carbocyclic aryl,
- carbocyclic arylthio,
- carbocyclic arylthio substituted by halogen,
- carbocyclic arylthio substituted by C₁₋₅ alkyl,
- carbocyclic arylsulfonyl,
- carbocyclic arylsulfonyl substituted by halogen,
- heterocyclylthio,
- heterocyclylthio substituted by C₁₋₅ alkyl,
- C₃₋₆ cycloalkyl,

265

- C₃₋₆ cycloalkenyl,
- carbocyclyl,
- carbocyclyl substituted by C₁₋₅ alkoxy,
- carbocyclic aryl, and
- carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

- halogen,
- nitro,
- C₁₋₅ alkyl, and
- C₁₋₅ alkyl substituted by substituent(s) independently selected from the group consisting of:

- halogen,
- carbocyclic aryl, and
- heterocyclyl,

- C₁₋₅ alkoxy,
- C₁₋₅ alkoxy substituted by halogen,
- C₁₋₅ alkoxy substituted by carbocyclic aryl,
- carbocyclic aryloxy,
- mono-carbocyclic arylaminocarbonyl, and
- mono-carbocyclic arylaminocarbonyl substituted by substituent(s) selected from the group consisting of:

- halogen,
- C₁₋₅ alkyl,
- C₁₋₅ alkoxy, and
- C₁₋₅ alkoxy substituted by halogen,

- di-carbocyclic arylaminocarbonyl, and
- di-carbocyclic arylaminocarbonyl substituted by substituent(s) selected from the group consisting of:

266

- halogen,
 - C₁₋₅ alkyl,
 - C₁₋₅ alkoxy, and
 - C₁₋₅ alkoxy substituted by halogen,
 - C₁₋₅ alkylthio,
 - C₁₋₅ alkylthio substituted by halogen,
 - C₁₋₅ alkylsulfonyl,
 - carbocyclic aryl, and
 - heterocyclyl,
 - heterocyclyl, and
 - heterocyclyl substituted by substituent(s) independently selected from the group consisting of:
 - C₁₋₅ alkyl,
 - C₁₋₅ alkoxy,
 - C₁₋₅ alkoxy substituted by carbocyclic aryl,
 - carbocyclic aryl, and
 - carbocyclic aryl substituted by halogen,
- (ii) C₂₋₅ alkenyl, and
- C₂₋₅ alkenyl substituted by substituent(s) independently selected from the group consisting of:
- carbocyclic aryl, and
 - carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
 - nitro,
 - halogen,
 - C₁₋₅ alkyl,
 - C₁₋₅ alkyl substituted by halogen,
 - C₁₋₅ alkoxy, and

••C₁₋₅ alkoxy substituted by halogen,

- (iii) C₃₋₆ cycloalkyl, and
C₃₋₆ cycloalkyl substituted by substituent(s) independently
selected from the group consisting of:
- C₁₋₅ alkyl,
 - C₁₋₅ alkyl substituted by carbocyclic aryl,
 - carbocyclic arylcarbonylamino, and
 - carbocyclic aryl,
- (iv) carbocyclyl, and
carbocyclyl substituted by nitro,
- (v) carbocyclic aryl, and
carbocyclic aryl substituted by substituent(s) independently
selected from the group consisting of:
- halogen,
 - cyano,
 - nitro,
 - C₁₋₉ alkyl, and
 - C₁₋₉ alkyl substituted by substituent(s) independently selected
from the group consisting of:
- halogen,
 - oxo,
 - mono-carbocyclic arylaminocarbonyl,
 - di-carbocyclic arylaminocarbonyl,
 - mono-carbocyclic arylaminocarbonyl substituted by C₁₋₅
alkoxy,
 - di-carbocyclic arylaminocarbonyl substituted by C₁₋₅
alkoxy,
 - carbocyclic aryloxy,

268

- carbocyclic aryl, and

- carbocyclic aryl substituted by substituent(s)

independently selected from the group consisting of:

- halogen,

- C₁₋₅ alkyl, and

- C₁₋₅ alkyl substituted by halogen,

- heterocyclyl, and

- heterocyclyl substituted by C₁₋₅ alkyl,

- C₂₋₅ alkenyl,

- C₁₋₇ alkoxy,

- C₁₋₇ alkoxy substituted by halogen,

- C₁₋₇ alkoxy substituted by carbocyclic aryl,

- C₃₋₆ cycloalkoxy,

- carbocyclic aryloxy, and

- carbocyclic aryloxy substituted by substituent(s) independently

selected from the group consisting of:

- halogen,

- nitro, and

- C₁₋₅ alkoxy

- heterocyclyloxy, and

- heterocyclyloxy substituted by substituent(s) independently

selected from the group consisting of:

- halogen,

- C₁₋₅ alkyl, and

- C₁₋₅ alkyl substituted by halogen,

- C₁₋₅ alkoxycarbonyl,

- mono-C₁₋₅ alkylaminocarbonyl,

- di-C₁₋₅ alkylaminocarbonyl,

- mono-C₁₋₅ alkylaminocarbonyl substituted by carbocyclic aryl,
- di-C₁₋₅ alkylaminocarbonyl substituted by carbocyclic aryl,
- mono-carbocyclic arylaminocarbonyl,
- di-carbocyclic arylaminocarbonyl,
- mono-carbocyclic arylaminocarbonyl substituted by C₁₋₅ alkyl,
- di-carbocyclic arylaminocarbonyl substituted by C₁₋₅ alkyl,
- mono-C₁₋₅ alkylamino,
- di-C₁₋₅ alkylamino,
- C₁₋₅ alkylthio,
- C₁₋₅ alkylthio substituted by halogen,
- C₁₋₅ alkylsulfonyl,
- carbocyclic aryl, and
- carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
 - C₁₋₇ alkyl, and
 - C₁₋₇ alkyl substituted by halogen,

- (vi) heterocyclyl, and
- heterocyclyl substituted by substituent(s) independently selected from the group consisting of:
- halogen,
 - C₁₋₅ alkyl, and
 - C₁₋₅ alkyl substituted by substituent(s) independently selected from the group consisting of:
 - halogen,
 - oxo,
 - carbocyclic aryl,
 - carbocyclic aryl substituted by halogen,
 - heterocyclyl, and

270

••heterocyclyl substituted by substituent(s) independently
selected from the group consisting of:

- halogen,
- C₁₋₅ alkyl, and
- C₁₋₅ alkyl substituted by halogen,

- C₁₋₅ alkoxy,
- C₁₋₅ alkylthio,
- carbocyclic arylthio,
- C₁₋₅ alkylsulfonyl,
- carbocyclic arylsulfonyl,
- carbocyclic arylsulfonyl substituted by halogen,
- carbocyclic arylsulfonyl substituted by C₁₋₅ alkyl,
- C₁₋₅ alkoxycarbonyl,
- carbocyclic aryl, and
- carbocyclic aryl substituted by substituent(s) independently
selected from the group consisting of:

- halogen,
- nitro, and
- C₁₋₅ alkyl,

- heterocyclyl, and
- heterocyclyl substituted by substituent(s) independently selected
from the group consisting of:

- halogen,
- C₁₋₅ alkyl, and
- C₁₋₅ alkyl substituted by halogen;

wherein carbocyclic aryl is phenyl, naphthyl, or anthranyl;
carbocyclyl is 1-oxo-indanyl, 9*H*-fluorenyl, 9-oxo-fluorenyl,

anthraquinonyl, *C*-fluoren-9-ylidene, indanyl, or menthyl;

heterocyclyl is 1,2,3,4-tetrahydro-isoquinolyl, 1,2,3-thiadiazolyl, 1,2,3-triazolyl, 1,3-dioxo-isoindolyl, 1*H*-indolyl, 1*H*-pyrrolyl, 2,3-dihydro-1-oxo-isoindolyl, 2,3-dihydro-benzo[1,4]dioxinyl, 2*H*-benzopyranyl, 2-oxo-benzopyranyl, 2-oxo-pyrrolidinyl, 4-oxo-benzopyranyl, 9*H*-xanthenyl, benzo[1,3]dioxolyl, benzo[2,1,3]oxadiazolyl, benzo[1,2,5]oxadiazolyl, benzo[*b*]thienyl, furyl, isoxazolyl, morpholinyl, oxazolyl, pyrazolyl, pyridyl, pyrimidyl, pyrrolidyl, quinolyl, quinoxalyl, thiazolyl, or thienyl;

halogen is fluoro, chloro, bromo, or iodo;

or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

13. The compound according to claim 12 wherein:

R_2 is C_{1-5} alkyl substituted by carbocyclic aryl, C_{1-5} alkyl substituted by halogenated carbocyclic aryl, C_{1-5} alkyl substituted by heterocyclyl, C_{1-5} alkyl substituted by halogenated heterocyclyl, carbocyclic aryl, carbocyclic aryl by halogen, heterocyclyl, heterocyclyl by halogen, or - $N(R_{2a})(R_{2b})$; wherein R_{2a} and R_{2b} are each independently hydrogen, C_{1-5} alkyl, C_{1-5} alkyl substituted by hydroxy, or C_{1-5} alkyl substituted by halogen;

L is Formula (IIIa); wherein R_3 and R_4 are each independently hydrogen or C_{1-5} alkyl; and A and B are each independently a single bond, $-CH_2-$, or $-(CH_2)_2-$;

Z_3 and Z_4 are each independently hydrogen, halogen, C_{1-5} alkyl, C_{1-5} alkyl substituted by halogen, mono- C_{1-5} alkyl amino, or di- C_{1-5} alkyl amino;

and

Y is $-C(O)-$, $-C(O)NR_5-$, $-C(S)NR_5-$, or $-(CH_2)_m-$; wherein R_5 is hydrogen or C_{1-5} alkyl; and m is 0, 1, or 2; Y is not $-(CH_2)_m-$ provided that either R_{2a} or R_{2b} is hydrogen;

or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

14. The compound according to claim 13 wherein R_1 is selected from the group consisting of:

- (i) C_{1-5} alkyl substituted by substituent(s) independently selected from the group consisting of:
 - hydroxy,
 - carbocyclic aryl,
 - carbocyclic aryl substituted by halogen, and
 - carbocyclic aryl substituted by halogenated C_{1-5} alkyl,
- (ii) carbocyclic aryl, and
carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
 - halogen,
 - cyano,
 - C_{1-5} alkyl,
 - C_{1-5} alkyl substituted by halogen,
 - C_{1-5} alkoxy, and
 - C_{1-5} alkoxy substituted by halogen,
- (iii) heterocyclyl, and
heterocyclyl substituted by halogen;

R_2 is C_{1-5} alkyl substituted by carbocyclic aryl or $-N(R_{2a})(R_{2b})$; wherein R_{2a} and R_{2b} are each independently hydrogen or C_{1-5} alkyl;

L is Formula (IIIa); wherein R_3 and R_4 are each hydrogen; and A and B are each a single bond;

Z_3 and Z_4 are each independently hydrogen, C_{1-5} alkyl, mono- C_{1-5} alkyl amino, or di- C_{1-5} alkyl amino;

and

273

Y is -C(O)-;

wherein carbocyclic aryl is phenyl;

heterocyclyl is furyl or pyridyl;

halogen is fluoro, chloro, or bromo;

or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

15. The compound according to claim 14 wherein R₁ is selected from the group consisting of:

carbocyclic aryl, and

carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

•halogen,

•cyano, and

•C₁₋₅ alkoxy;

Z₃ is hydrogen when Z₄ is C₁₋₅ alkyl; or Z₃ is C₁₋₅ alkyl, mono-C₁₋₅ alkyl amino, or di-C₁₋₅ alkyl amino when Z₄ is hydrogen;

or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

16. The compound according to claim 1 selected from the group consisting of:

3-chloro-*N*-(*cis*-4-{[2-(dimethylamino)-6-methylpyrimidin-4-yl]amino}cyclohexyl)-4-fluorobenzamide;

N-(*cis*-4-{[2-(dimethylamino)-6-methylpyrimidin-4-yl]amino}cyclohexyl)-3,4-difluorobenzamide;

N-[*cis*-4-(2-dimethylamino-5-methyl-pyrimidin-4-ylamino)-cyclohexyl]-3-methoxy-benzamide;

N-[*cis*-4-(2-dimethylamino-5-methyl-pyrimidin-4-ylamino)-cyclohexyl]-3-trifluoromethyl-benzamide;

N-[*cis*-4-(2-dimethylamino-5-methyl-pyrimidin-4-ylamino)-cyclohexyl]-3,5-bis-trifluoromethyl-benzamide;

2,2-difluoro-benzo[1,3]dioxole-5-carboxylic acid [*cis*-4-(2-dimethylamino-5-methyl-pyrimidin-4-ylamino)-cyclohexyl]-amide;

4-cyano-*N*-[*cis*-4-(2-dimethylamino-5-methyl-pyrimidin-4-ylamino)-cyclohexyl]-benzamide;

4-chloro-*N*-[*cis*-4-(2-dimethylamino-5-methyl-pyrimidin-4-ylamino)-cyclohexyl]-benzamide;

N-[*cis*-4-(2-dimethylamino-5-methyl-pyrimidin-4-ylamino)-cyclohexyl]-3-ethyl-benzamide;

N-[*cis*-4-(2-dimethylamino-5-methyl-pyrimidin-4-ylamino)-cyclohexyl]-3,4-difluoro-benzamide;

5-bromo-*N*-[*cis*-4-(2-dimethylamino-5-methyl-pyrimidin-4-ylamino)-cyclohexyl]-nicotinamide;

5-bromo-furan-2-carboxylic acid [*cis*-4-(2-dimethylamino-5-methyl-pyrimidin-4-ylamino)-cyclohexyl]-amide;

3,5-dibromo-*N*-[*cis*-4-(2-dimethylamino-5-methyl-pyrimidin-4-ylamino)-cyclohexyl]-benzamide;

N-[*cis*-4-(2-dimethylamino-5-methyl-pyrimidin-4-ylamino)-cyclohexyl]-3-ethoxy-benzamide;

2-(3,5-bis-trifluoromethyl-phenyl)-*N*-[*cis*-4-(2-dimethylamino-5-methyl-pyrimidin-4-ylamino)-cyclohexyl]-2-hydroxy-acetamide;

2-(4-bromo-phenyl)-*N*-[*cis*-4-(2-dimethylamino-5-methyl-pyrimidin-4-ylamino)-cyclohexyl]-2-hydroxy-acetamide;

N-[*cis*-4-(2-dimethylamino-5-methyl-pyrimidin-4-ylamino)-cyclohexyl]-3,5-diethoxy-benzamide;

3-bromo-*N*-[*cis*-4-(2-dimethylamino-5-methyl-pyrimidin-4-ylamino)-cyclohexyl]-4-fluoro-benzamide;

N-[*cis*-4-(2-dimethylamino-6-methyl-pyrimidin-4-ylamino)-cyclohexyl]-3-ethoxy-benzamide;

N-[*cis*-4-(2-dimethylamino-6-methyl-pyrimidin-4-ylamino)-cyclohexyl]-3-trifluoromethyl-benzamide;

N-[*cis*-4-(2-dimethylamino-6-methyl-pyrimidin-4-ylamino)-cyclohexyl]-3,5-bis-trifluoromethyl-benzamide;

2,2-difluoro-benzo[1,3]dioxole-5-carboxylic acid [*cis*-4-(2-dimethylamino-6-methyl-pyrimidin-4-ylamino)-cyclohexyl]-amide;

4-chloro-*N*-[*cis*-4-(2-dimethylamino-6-methyl-pyrimidin-4-ylamino)-cyclohexyl]-benzamide;

N-[*cis*-4-(2-dimethylamino-6-methyl-pyrimidin-4-ylamino)-cyclohexyl]-3-ethyl-benzamide;

N-[*cis*-4-(2-dimethylamino-6-methyl-pyrimidin-4-ylamino)-cyclohexyl]-4-methyl-benzamide;

5-bromo-*N*-[*cis*-4-(2-dimethylamino-6-methyl-pyrimidin-4-ylamino)-cyclohexyl]-nicotinamide;

5-bromo-furan-2-carboxylic acid [*cis*-4-(2-dimethylamino-6-methyl-pyrimidin-4-ylamino)-cyclohexyl]-amide;

3,5-dibromo-*N*-[*cis*-4-(2-dimethylamino-6-methyl-pyrimidin-4-ylamino)-cyclohexyl]-benzamide;

N-[*cis*-4-(2-dimethylamino-6-methyl-pyrimidin-4-ylamino)-cyclohexyl]-3-ethoxy-benzamide;

2-(3,5-bis-trifluoromethyl-phenyl)-*N*-[*cis*-4-(2-dimethylamino-6-methyl-pyrimidin-4-ylamino)-cyclohexyl]-2-hydroxy-acetamide;

2-(4-bromo-phenyl)-*N*-[*cis*-4-(2-dimethylamino-6-methyl-pyrimidin-4-ylamino)-cyclohexyl]-2-hydroxy-acetamide;

N-[*cis*-4-(2-dimethylamino-6-methyl-pyrimidin-4-ylamino)-cyclohexyl]-3,5-diethoxy-benzamide; and

3-bromo-*N*-[*cis*-4-(2-dimethylamino-6-methyl-pyrimidin-4-ylamino)-cyclohexyl]-4-fluoro-benzamide;

or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

17. The compound according to claim 1 selected from the group consisting of:

3-chloro-*N*-(*cis*-4-{[2-(dimethylamino)pyrimidin-4-yl]amino}cyclohexyl)-4-fluorobenzamide;

N-(*cis*-4-{[2,6-bis(dimethylamino)pyrimidin-4-yl]amino}cyclohexyl)-3,4-difluorobenzamide;

N-(*cis*-4-{[2-benzyl-6-(dimethylamino)pyrimidin-4-yl]amino}cyclohexyl)-3-chloro-4-fluorobenzamide;

3,4-dichloro-*N*-[*cis*-4-(2-dimethylamino-6-methyl-pyrimidin-4-ylamino)-cyclohexyl]-benzamide;

4-cyano-*N*-[*cis*-4-(2-dimethylamino-6-methyl-pyrimidin-4-ylamino)-cyclohexyl]-benzamide;

N-[*cis*-4-(2-dimethylamino-6-methyl-pyrimidin-4-ylamino)-cyclohexyl]-3,4-diethoxy-benzamide;

3-chloro-*N*-[*cis*-4-(2-dimethylamino-6-methyl-pyrimidin-4-ylamino)-cyclohexyl]-5-fluoro-benzamide;

N-[*cis*-4-(2-dimethylamino-5-methyl-pyrimidin-4-ylamino)-cyclohexyl]-3,5-dimethoxy-benzamide;

3,4-dichloro-*N*-[*cis*-4-(2-dimethylamino-5-methyl-pyrimidin-4-ylamino)-cyclohexyl]-benzamide;

N-[*cis*-4-(2-dimethylamino-5-methyl-pyrimidin-4-ylamino)-cyclohexyl]-3,4-diethoxy-benzamide; and

3-chloro-*N*-[*cis*-4-(2-dimethylamino-5-methyl-pyrimidin-4-ylamino)-cyclohexyl]-5-fluoro-benzamide;

or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

18. The compound according to claim 11 wherein:

R₁ is selected from hydrogen, -CO₂tBu, or -CO₂Bn (Bn is a benzyl group);

R₂ is C₁₋₅ alkyl substituted by carbocyclic aryl, C₁₋₅ alkyl substituted by

halogenated carbocyclic aryl, C₁₋₅ alkyl substituted by heterocyclyl, C₁₋₅ alkyl substituted by halogenated heterocyclyl, carbocyclic aryl, carbocyclic aryl by halogen, heterocyclyl, heterocyclyl by halogen, or -N(R_{2a})(R_{2b}); wherein R_{2a} and R_{2b} are each independently hydrogen, C₁₋₅ alkyl, C₁₋₅ alkyl substituted by hydroxy, or C₁₋₅ alkyl substituted by halogen;

L is Formula (IIIa); wherein R₃ and R₄ are each independently hydrogen or C₁₋₅ alkyl; and A and B are each independently a single bond, -CH₂-, or - (CH₂)₂-;

Z₃ and Z₄ are each independently hydrogen, halogen, C₁₋₅ alkyl, C₁₋₅ alkyl substituted by halogen, mono-C₁₋₅ alkyl amino, or di-C₁₋₅ alkyl amino; and Y is a single bond;

or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

19. The compound according to claim 18 wherein:

R₂ is C₁₋₅ alkyl substituted by carbocyclic aryl or -N(R_{2a})(R_{2b}); wherein R_{2a} and R_{2b} are each independently hydrogen or C₁₋₅ alkyl;

L is Formula (IIIa); wherein R₃ and R₄ are each hydrogen; and A and B are each a single bond; and

Z₃ and Z₄ are each independently hydrogen, C₁₋₅ alkyl, mono-C₁₋₅ alkyl amino, or di-C₁₋₅ alkyl amino;

wherein carbocyclic aryl is phenyl;

heterocyclyl is furyl or pyridyl;

halogen is fluoro, chloro, or bromo;

or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

20. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of claims 1 to 19 in combination with a pharmaceutically acceptable carrier.

21. A method for the prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction comprising administering to an individual suffering from said condition a therapeutically effective amount of a compound according to any one of claims 1 to 19 or a pharmaceutical composition according to claim 20.
22. A method for the prophylaxis or treatment of an eating disorder, obesity or an obesity related disorder comprising administering to an individual suffering from said condition a therapeutically effective amount of a compound according to any one of claims 1 to 19 or a pharmaceutical composition according to claim 20.
23. A method for the prophylaxis or treatment of anxiety, depression, schizophrenia, addiction, or epilepsy comprising administering to an individual suffering from said condition a therapeutically effective amount of a compound according to any one of claims 1 to 19 or a pharmaceutical composition according to claim 20.
24. A compound according to any one of claims 1 to 19 or a pharmaceutical composition according to claim 20 for use in a method of treatment of the human or animal body by therapy.
25. A compound according to any one of claims 1 to 19 or a pharmaceutical composition according to claim 20 for use in a method of prophylaxis or treatment of an eating disorder, obesity or an obesity related disorder of the human or animal body by therapy.
26. A compound according to any one of claims 1 to 19 or a pharmaceutical composition according to claim 20 for use in a method of prophylaxis or treatment of anxiety, depression, schizophrenia, addiction, or epilepsy of the human or

animal body by therapy.

27. A compound according to any one of claims 1 to 19 for the manufacture of a medicament for use in the prophylaxis or treatment of an eating disorder, obesity or obesity related disorders.
28. A compound according to any one of claims 1 to 19 for the manufacture of a medicament for use in the prophylaxis or treatment of anxiety, depression, schizophrenia, addiction, or epilepsy.
29. A method of decreasing food intake of an individual comprising administering to said individual a therapeutically effective amount of a compound according to any one of claims 1 to 19 or a pharmaceutical composition according to claim 20.
30. A method of inducing satiety in an individual comprising administering to said individual a therapeutically effective amount of a compound according to any one of claims 1 to 19 or a pharmaceutical composition according to claim 20.
31. A method of controlling or reducing weight gain in an individual comprising administering to said individual a therapeutically effective amount of a compound according to any one of claims 1 to 19 or a pharmaceutical composition according to claim 20.
32. A method of modulating a MCH receptor in an individual comprising contacting the receptor with a compound according to any one of claims 1 to 19.
33. The method of modulating the MCH receptor according to claim 32 wherein the compound is an antagonist.
34. The method of modulating the MCH receptor according to claims 32 or 33 wherein the modulation of the MCH receptor is for the prophylaxis or treatment of an eating disorder, obesity or obesity related disorder.
35. The method of modulating the MCH receptor according to claims 32 or 33 wherein the modulation of the MCH receptor reduces food intake of the individual.
36. The method of modulating the MCH receptor according to claims 32 or 33 wherein the modulation of the MCH receptor induces satiety in the individual.

37. The method of modulating the MCH receptor according to claims 32 or 33 wherein the modulation of the MCH receptor controls or reduces weight gain of the individual.
38. The method of modulating the MCH receptor according to claims 32 or 33 wherein the modulation of the MCH receptor is for prophylaxis or treatment of anxiety, depression, schizophrenia, addiction, or epilepsy.
39. The method of modulating the MCH receptor according to any one of claims 22, 23 and 29 to 38 wherein the individual is a mammal.
40. The method of modulating the MCH receptor according to claim 39 wherein the mammal is a human.
41. The method according to claim 40 wherein the human has a body mass index of about 18.5 to about 45.
42. The method according to claim 41 wherein the human has a body mass index of about 25 to about 45.
43. The method according to claim 42 wherein the human has a body mass index of about 30 to about 45.
44. The method according to claim 43 wherein the human has a body mass index of about 35 to about 45.
45. A method of producing a pharmaceutical composition comprising admixing a compound according to any one of claims 1 to 19 and a pharmaceutically acceptable carrier.